FATE NASDAQ
Credit Risk of going bust: higher than 85% of companies Debt: 23.9% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.11 (down 95%), Fate Therapeutics, Inc. would be worth roughly what it owes.
Total debt $75.7M against a stock market value of $241.3M.
Distance to default 2.16 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $37.8M (short-term plus half of long-term), stock volatility 91.5%; Altman Z'' -18.59. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
San Diego, CA 92131
US
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| TAHL CINDY | S-Sale | 38,800 | $2.46 | 2026-08-04 |
| Valamehr Bahram | S-Sale | 43,947 | $2.46 | 2026-08-04 |
| Xu Yuan | A-Award | 87,900 | $2.06 | 2026-06-12 |
| Jooss Karin | A-Award | 87,900 | $2.06 | 2026-06-12 |
| EPSTEIN ROBERT S | A-Award | 87,900 | $2.06 | 2026-06-12 |